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Abstract
Background: In this retrospective study we evaluated the respective correlations and clinical relevance of FOLR1
mRNA expression, FOLR1 promoter specific methylation and global DNA hypomethylation in type I and type II
ovarian cancer.
Methods: Two hundred fifty four ovarian cancers, 13 borderline tumours and 60 samples of healthy fallopian
epithelium and normal ovarian epithelium were retrospectively analysed for FOLR1 expression with RT-PCR. FOLR1
DNA promoter methylation and global DNA hypomethylation (measured by means of LINE1 DNA hypomethylation)
were evaluated with MethyLight technique.
Results: No correlation between FOLR1 mRNA expression and its specific promoter DNA methylation was found
neither in type I nor in type II cancers, however, high FOLR1 mRNA expression was found to be correlated with
global DNA hypomethylation in type II cancers (p = 0.033). Strong FOLR1 mRNA expression was revealed for Grades
2-3, FIGO stages III-IV, residual disease > 0, and serous histotype. High FOLR1 expression was found to predict
increased platinum sensitivity in type I cancers (odds ratio = 3.288; 1.256-10.75; p = 0.020). One-year survival analysis
showed in type I cancers an independent better outcome for strong expression of FOLR1 in FIGO stage III and IV.
For the entire follow up period no significant independent outcome for FOLR1 expression was revealed. In type I
cancers LINE 1 DNA hypomethylation was found to exhibit a worse PFS and OS which were confirmed to be
independent in multivariate COX regression model for both PFS (p = 0.026) and OS (p = 0.012).
Conclusion: No correlations were found between FOLR1 expression and its specific promoter methylation, however,
high FOLR1 mRNA expression was associated with DNA hypomethylation in type II cancers. FOLR1 mRNA expression
did not prove to predict clinical outcome in type II cancers, although strong FOLR1 expression generally denotes
ovarian cancers with highly aggressive phenotype. In type I cancers, however, strong FOLR1 expression has been
found to be a reliable indicator of improved platinum responsiveness reflecting a transient better one-year follow up
outcome in highly FOLR1 expressing type I cancers. An independent prognostic role of global DNA hypomethylation
was demonstrated in type I tumours.
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Background
Ovarian carcinomas account for the highest mortality
among all gynecological cancers in the world [1]. Despite
aggressive treatment including highly offensive surgical
cytoreduction and multiagent chemotherapy, the prog-
nosis of patients with advanced ovarian cancer remains
unacceptably poor.
Folic acid is an essential component in DNA synthesis,
replication and repair, protein synthesis and methylation
reactions. This is especially true for rapidly dividing cells
[2]. Three different mechanisms exist for cellular folate
uptake: one via the membrane-associated Folate Receptor
(FOLR) and the physiologically more important mechan-
ism via the Reduced Folate Carrier (RFC). More recently,
a third, the proton-coupled folate transporter, responsible
exclusively for the intestinal uptake of folate, was identi-
fied [3, 4]. FOLR internalizes folates by means of receptor
mediated endocytosis and RFC uses a bidirectional anion-
exchange mechanism to transport folates into cytoplasm
[5, 6]. Human FOLR is encoded by a family of genes
whose homologous products are the FOLR types -α, -β
and –γ.
Principally FOLR isoforms α and β are capable of
transporting folate into cells, but generally the ubiqui-
tously expressed RFC is exclusively used for this purpose
by adult tissues [7]. In fact, most normal tissues virtually
lack FOLR, and its physiologic importance appears to be
confined to situations where the availability of folate is
limited [8].
In contrast, the ability of FOLR1 (encodes for folate
receptor α) to bind folate has been demonstrated in
malignant tissue [9, 10]. Under such pathological
circumstances FOLR1 may be overexpressed to increase
folate uptake in order to cope with the augmented turn-
over of nucleic acid synthesis and reparation during
accelerated cellular growth [11, 12]. FOLR1 was found
to be strongly expressed in renal, pancreatic, endometrial
carcinomas, squamous cervical cancer and ovarian cancer
[13]. Furthermore, FOLR1 is reported to be expressed in
the majority of non-mucinous epithelial ovarian cancers at
levels 10- to 100-fold higher than its normal expression in
the kidney and on lung and breast epithelial cells [14].
Recently, it was shown that FOLR1 can be exploited for
specific delivery of drugs linked to folic acid into ovarian
cancer cells. Proof of principle was provided with folate-
desacetyl vinblastine monohydrazide (Vintafolide®) in the
clinical PRECEDENT trial in ovarian cancer. Moreover,
companion diagnostics with radio-labelled folate (Etarfola-
tide®) -based tumour imaging has been found to predict
response to Vintafolide® [15].
Furthermore, folic acid is crucially involved in DNA
methylation via metabolic cycling of methionine towards
homocysteine. Epigenetic modifications of DNA through
CpG site methylation are recognized to play a fundamental
role in tumorigenesis. Two distinct DNA methylation
abnormalities are observed in cancer. The first is a global
genome-wide reduction of DNA methylation (global DNA
hypomethylation) and the second is hypo- or hyper-
methylation within the CpG islands within specific gene
promoters. Promoter hypomethylation is believed to in-
duce proto-oncogene activation, and global DNA hypome-
thylation is strongly related to chromosomal instability.
Regional hypermethylation is strongly associated with
transcriptional silencing of specific genes (e.g., tumour
suppressor genes) [16]. A global decrease in the amount of
cellular cytosine methylation is observed in many neoplas-
tic tissues and is related to poor prognosis or clinical sever-
ity in several cancer types, including ovarian cancer [17].
The majority of global DNA hypomethylation occurs at
repetitive elements, such as long interspersed nuclear ele-
ments (LINEs) [18]. Genome-wide DNA hypomethylation
at LINE1 elements during tumorigenesis is presumed to
contribute crucially to chromosomal instability [19].
Some authors [20–22] have proposed a potential role of
epigenetic regulation in FOLR1 expression through methy-
lation, but the evidence was not conclusive. Nevertheless,
epigenetic changes can offer a plausible explanation for
elevated FOLR1 expression in some tumours [23].
The purpose of the study presented here was to ana-
lyse the clinical relevance of FOLR1 mRNA expression
and its possible influence on global DNA methylation
status in ovarian cancer. Furthermore, we were inter-
ested in elucidating whether FOLR1 mRNA expression
is mainly regulated by DNA methylation of its promoter.
In addition, the role of FOLR1 expression was assessed
as predictive markers of platinum responsiveness. We
were especially interested in conducting these analyses
regarding the histologic subtypes and the ovarian cancer
dualistic typology proposed by Kurman et al. [24, 25].
Methods
Patients and samples
Two hundred fifty four ovarian cancer samples were
retrospectively analysed from 1989 to 2010 at the
Medical University of Innsbruck. The study was per-
formed in accordance with the principles of the Helsinki
Declaration after approval by the local ethics committee.
Median age was 61.58 years. Median follow-up was
55 months (1-289 m). After surgery patients mostly
received chemotherapy as a standard treatment. A
minority of them (12 pts) underwent neoadjuvant
treatment (at least three courses of chemotherapy
followed by interval debulking surgery); these patients
were excluded from the platinum response risk analysis.
The majority received adjuvant chemotherapy platinum-
based therapy. Staging was performed according to the
International Federation of Gynecology and Obstetrics
(FIGO) classification. All FIGO stages and all histotypes
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were included. The clinico-pathological characteristics
are reported in Table 1. According to the dualistic model
proposed by Kurman et al. we divided the cancers cohort
into type I and type II [24, 25]. Clinical, pathological and
follow-up data were stored in a database in accordance
with hospital privacy rules. Tumour samples and clinical
data were collected after written informed consent of
patients. After primary treatment, all patients were moni-
tored by our department at intervals increasing from three
months to one year until death or the end of the study.
Follow-up information was available for all patients.
Overall survival was defined as the time from diag-
nosis to last follow-up or death and progression-free
survival as the time from diagnosis to first recur-
rence. Median overall survival (OS) was 55.00 months
(Q25-Q75 22.00-96.25), and median progression-free
survival (PFS) was 25.00 months (Q25-Q75 10.00-
74.25). To define sensitivity to platinum we calcu-
lated the time from the last course of chemotherapy
as defined by Markman et al. [26]. Moreover, we
analysed tissues from 60 healthy controls (23 tubes
with fimbriae and 36 normal ovarian epithelial
tissues) and from 13 ovarian borderline tumours.
Median age of patients with borderline tumours was
54 years and 51 years for controls; we did not find any
general association between age and FOLR1 mRNA
levels (rs = 0.044, p = 0.485). In borderline tumors there
were nine patients with serous and four patients with
mucinous tumours. Nine patients had FIGO stage I and
four patients FIGO stage II borderline disease.
RNA extraction and reverse transcription
Tumour specimens were obtained immediately after
surgery and brought to our pathologist. Part of the tissue
was pulverized under cooling with liquid nitrogen and
stored at -80 °C. Total cellular RNA extraction and
reverse transcription of RNA were performed as recently
described [27].
FOLR1 mRNA expression analysis
Primers and probes for the TATA box-binding protein
(TBP; a component of the DNA-binding protein com-
plex TFIID as an endogenous RNA control) were used
as described by Bieche et al. [28]. Primers and probes for
FOLR1 were determined using the computer program
Primer Express (Life Technologies, Carlsbad, CA, USA).
BLASTN searches were conducted to confirm the total
gene specificity of the nucleotide sequences chosen for
the primers and probes. To prevent amplification of
contaminating genomic DNA, the probe was placed at
the junction between two exons. FOLR1 forward primer:
5′-CTG GCT GGT GTT GGT AGA ACA G -3′;
FOLR1 reverse-primer: 5′- AGG CCC CGA GGA CAA
GTT-3′; FOLR1 TaqMan probe: 5′-CAT TCT TCC
TCC AGG GTC GAC ACT GCT-3′-BHQ1.
Table 1 Clinico-pathological features with univariate survival analysis in type I and type II ovarian cancers
Type 1 Type 2
Median
(years)










Age 59 49-73 122 62 55-71 132
Histology Serous 11 9.0 % 119 90.2 %
Endometrioid 57 46.7 % 13 9.8 %
Mucinous 41 33.6 % 0 0.0 %
Clear cell 13 10.7 % 0.076 0.123 0 0.0 % 0.007 0.004
FIGO stage I 54 44.3 % 15 11.4 %
II 7 5.7 % 11 8.3 %
III 53 43.4 % 88 66.7 %
IV 8 6.6 % <0.0001 0.003 18 13.6 % 0.002 0.044
Tumour grade 1 27 22.1 % 0 0.0 %
2 64 52.5 % 66 50.0 %
3 31 25.4 % 0.008 0.015 66 50.0 % 0.406 0.087
Residual disease RD = 0 80 65.6 % 44 33.3 %
RD > 0 42 34.4 % <0.0001 <0.0001 88 66.7 % <0.0001 <0.0001
Chemotherapy None 21 17.2 % 7 5.3 %
Adjuvant 100 81.9 % 111 84.1 %
Neoadjuvant 0 0.0 % 12 9.1 %
Q = quartile; 1 = 25° 3 = 75°
Notaro et al. BMC Cancer  (2016) 16:589 Page 3 of 13
PCR reactions were performed using an ABI Prism
7900HT Detection System (Applied Biosystems, Foster
City, CA, USA) as recently described [27].
DNA isolation and DNA methylation analysis
Genomic DNA from lyophilized, quick-frozen ovarian
cancer specimens was isolated using the DNeasy tissue kit
(Qiagen, Hilden, Germany). Bisulfite modification was
performed using the EZ DNA Methylation-Gold Kit
(Zymo Research, Orange, CA, USA) according to the
manufacturer’s instructions. MethyLight analysis was done
as described previously [29]. The PMR value (percentage
of fully methylated reference) was calculated to determine
the DNA methylation measurement.
Primers and probes for COL2A1 were described
recently [29]. Primers and probes for FOLR1 were
determined with the computer program Primer Express
(Life Technologies, Carlsbad, CA, USA) to produce a
74-base-pair PCR amplicon (nucleotide positions
17662066-17662139 as defined by NCBI Reference
Sequence NT_167190.2; gi|568815271) with a mean
distance of -2.384 base pairs, to the transcription start
site. The CpG island in the analysed gene was identified
using the CpG island searcher (http://www.uscnorris.com/
cpgislands/cpg.cgi) that screens for CpG islands that meet
the criteria and algorithm described by Daiya Takai and
Peter A. Jones [30]. The following primers were used for
MethyLight PCR: FOLR1: Forward: 5′-CTC GAT CTC
CTA ACC TCG TAA TCC-3′; Reverse: 5′-TAT GGT
GGT TCG CGT TTG TAA TT-3′, TQM-probe: 6-FAM-
5′- CCC GCC TCG ACC TCC CAA AAT ACT T-3′-
BHQ1;
LINE1 DNA-hypomethylation was analysed as recently
described previously [29]; the levels of unmethylated re-
petitive elements were expressed as percent of unmethy-
lated reference (PUMR) values and were calculated
similarly to PMR (percentage of methylated reference)
values except that bisulfite-converted human sperm
DNA was used as an unmethylated reference for PUR
determinations.
Statistical analyses
To compare variables between two groups we used the
Mann-Whitney U Test and between more than two
groups Kruskal Wallis test. Analysis of survival was
performed with Kaplan-Meier curves and log-rank test.
The Cox regression analysis was used for multivariate
survival analysis. To eliminate variables we applied a
backward variable selection procedure. A p value of 0.1
was used to exclude variables; all other tests were
performed using a 0.05 % level of significance. Risk was
analysed with odds ratio and chi-square tests and Fisher's
exact test to evaluate significant values. Correlations were
performed with Spearman's rank test. All statistical
analyses were performed using SPSS, version 22.
Results
Correlation between FOLR1 mRNA expression and FOLR1
promoter methylation
Neither in the whole cohort of ovarian cancers nor in the
analysed type I and type II cancers a significant correlation
between the expression of FOLR1 and its specific promoter
methylation was revealed (Additional file 1: Figure S1).
FOLR1 mRNA expression in ovarian cancer
In the unselected cohort of examined ovarian cancers,
FOLR1 mRNA expression with a median value of 9.14
(arbitrary units normalized to TBP) was significantly
stronger than in borderline tumours (median value: 1.88;
p = 0.01) and in healthy controls (median value: 0.49;
p < 0.0001) (Fig. 1a). In healthy control tissues, normal
fimbriae of the fallopian tube (median value: 11.13) had
stronger FOLR1 expression than normal ovarian epithelial
tissue (median value: 0.16; p < 0.0001; Fig. 1b). In border-
line tumors FOLR1 expression did not differ between ser-
ous and mucinous histotypes (Fig. 1c). In cancers FOLR1
was significantly stronger in type II (median value: 14.24)
than in type I (median value: 4.75; p < 0.0001: Fig. 1d).
Two orders of magnitude can be distinguished regard-
ing FOLR1 expression: one is the clustering of type I
cancers together with borderline tumours and healthy
ovarian epithelium and the second is the merging of type
II cancers with healthy fallopian epithelium. The mean
of mRNA expression of FOLR1 was 5.68 times higher in
the second cluster compared to the first.
Table 2 shows differences in FOLR1 mRNA expression
according to the classical clinico-pathological characteris-
tics. Noteworthy is the significant higher levels of FOLR1
mRNA expression in high grade cancers, advanced stage,
non-optimally debulked tumors and in platinum sensitive
cancers. In serous histotypes FOLR1 expression was sig-
nificantly higher than in non-serous cancer and in mucin-
ous histotypes FOLR1 mRNA expression presented the
lowest values (median value 2.99).
FOLR1 mRNA expression and clinical outcome
In univariate survival analysis, when the cohort of cancers
was dichotomized along the median value in high and low
FOLR1 expression cancers, we revealed significantly
reduced PFS (p = 0.022) and OS (p = 0.029) in cancers
with strong FOLR1 mRNA expression. (Figure 2) This
could not be confirmed in multivariate analysis (Additional
file 2: Table S1). Univariate analysis, performed separately
for type I and type II cancers, did not show significant re-
sults (Additional file 3: Figure S2). Figure 2 depicts survival
curves stratified with regard to FIGO stage. Noteworthy is
the significant worse PFS for high values of FOLR1 in
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FIGO stage I and II, which was not verified when type I
and II cancers were analysed separately (Additional file 3:
Figure S2). This was not confirmed in multivariate analysis.
It should be emphasised that during the first year
follow-up strong expression of FOLR1 is significantly
associated with better OS (p = 0.028). This tendency was
also observed for PFS, but did not reach statistical
significance (p = 0.226). When this one year analysis was
performed separately in type I and type II cancers, no
significant difference was found, but when stratification
according to FIGO stage was performed, a small signifi-
cant better PFS and OS for high levels of FOLR1
transcripts in type I cancers was revealed for FIGO stage
III and IV (Fig. 3). This was confirmed in a multivariate
COX regression analysis (Table 3).
The odds ratio to predict platinum refractority/re-
sistance in case of high FOLR1 expression cancers, in
the whole cohort, was 2.013 (1.086-3.731) p = 0.018.
Moreover, performing the same analysis separately in
type I and type II cancers, this odds ratio was
increased to 3.288 (1.256-10.75; p = 0.020) in type I
cancers. However, in type II cancers, results on
platinum responsiveness were no longer significant
(1.877, 0.833-4.226, p = 0.126).
A B
C D
Fig. 1 FOLR1 expression in healthy tissues, borderline tumours and cancers. FOLR1 mRNA expression (median values) in a) healthy controls
(normal fimbriae and ovarian surface epithelium), borderline ovarian tumours (all histotypes) and ovarian cancers (all histotypes); b) in healthy
fimbriae compared to healthy ovarian epithelium (p < 0.0001); c) in serous compared to mucinous borderline ovarian tumors (n.s.); d) in type I
and type II ovarian cancers (p < 0.0001); Mann-Whitney test was applied (*P < 0.05, **P < 0.005, ***P < 0.0001). Units: arbitrary units normalized to
TBP. Error bars: 95 % CI
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Correlation between FOLR1 mRNA expression and global
DNA hypomethylation
As folate is an indirect supplier of methyl groups for
general methylation processes in cells, one other aim of
this work was to examine whether mRNA expression of
FOLR1 was associated with the degree of global DNA
methylation in ovarian cancer cells.
Analyses for global DNA hypomethylation were per-
formed in the cancer cohort based on the methylation
status of LINE1 as the principle surrogate marker.
Expression of FOLR1 was strongly associated with
global DNA hypomethylation. This was shown by a
significantly positive correlation between FOLR1 mRNA
expression and unmethylated LINE1 repetitive elements
measured by MethyLight PCR (LINE1-UR) (rs = 0.298,
p = 0.05). This relationship between global DNA hypome-
thylation and FOLR expression was observed in type II
cancers (rs = 0.390, p = 0.033), but not in type I cancers.
Global DNA hypomethylation and clinical outcome
In Table 2 LINE1 hypomethylation values according to
the main clinico-pathological parameters are shown. No
significant differences were detected.
Using the median value of LINE1 DNA hypomethyla-
tion in the cancer cohort (121.95) as the cut off value we
distinguished two groups, patients with high and patients
with low degree of LINE1 DNA hypomethylation in their
tumors. In univariate analysis we disclosed that only in
type I cancers both PFS (p = 0.011) and OS (p = 0.006)
were reduced in high degree of LINE1 DNA hypomethy-
lated cancers (Fig. 4). Independency of the latter results
was confirmed in a multivariate COX-regression model
both for PFS and OS (Table 4). However, no relevance on
clinical outcome was revealed in type II cancers for global
LINE1 hypomethylation.
Discussion
The study presented here analysed FOLR1 mRNA expres-
sion, its promoter DNA methylation and global DNA
hypomethylation in ovarian cancer and focused especially
on differences between type I and type II cancers. To the
best of our knowledge no specific investigations of this
issue have been performed to date in ovarian cancer, even
though, the study presented here certainly has some limits
such as its intrinsic retrospective design and consequently
the lack of statistical balance in the analysed subgroups
that inevitably leads to structural bias.
We were unable to evidence a relevant relationship be-
tween FOLR1 mRNA expression and the specific FOLR1
promoter methylation. This was also true when type I
Table 2 Differences in FOLR1 mRNA expression and LINE1 DNA hypomethylation according to classical clinico-pathological characteristics
FOLR1 mRNA expressiona LINE1-DNA hypomethylationb
Median value p-value1 Median value p-value1
Age (median value) Lower 9.96 102.81
Higher 8.88 0.714 171.82 0.826
G1 VS G2-3 G1 2.55 88.40
G2-3 10.63 0.010** 138.34 0.436
FIGO stage FIGO I, II 5.28 94.30
FIGO III, IV 11.94 <0.0001** 151.05 0.305
Residual disease RD = 0 6.45 96.14 0.407
RD > 0 12.64 <0.0001** 152.06
Histology Serous 14.04 118.29
Endometrioid 10.24 138.34
Clear cells 7.60
Mucinous 2.99 <0.0001** 104.06 0.533
Serous 14.04 118.29
Non-serous 6.00 <0.0001** 125.62 0.602
Mucinous 2.99 104.06
Non-mucinous 11.83 125.62 0.337
Platinum response Refractory/resistant 6.82 0.049* 177.82 0.313
Sensitive 11.68 117.71
Type I/II Type I 5.83 114.84
Type II 14.59 <0.0001** 134.67 0.345
1Mann Whitney Test. *Significant at the 0.05 level, **Significant at the 0.01 level, aArbitrary units normalized to TBP, bPUMR values
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and type II cancers were evaluated separately. There is
only a small CpG-island upstream of the transcription
stat site of FOLR1 (-2552 to -2331 bp; 222 bp region
containing 11 CpGs). 7 of these 11 CpG sites are cov-
ered by our MethyLight PCR reaction. Recently Stewart
et al. [31] analysed the impact of a decitabine treatment,
a DNA demethylating agent, on the expression of RhoA,
FOLR1 and RFC1 in 31 tumour patients. They observed
that there was no increase in FOLR1 protein expression
after a treatment with decitabine. Therefore, taken all
these together, it seems that DNA methylation does not
play a relevant role in the regulation of FOLR1 expression.
The dualistic typology described by Kurman et al.
[24, 25] is based on the different origin and pathogenesis
of both types of ovarian cancers Type I tumours are
typically more indolent and frequently diagnosed in stage
I. They are characterized by specific DNA mutations that
perturb signalling pathways [24, 32], but exhibit relative
genetic stability and are thought to develop from well-
established precursors, the borderline tumours [24]. The
more aggressive type II tumours (largely represented by
high-grade serous cancers) are typically present at an
advanced stage, with higher fatality and are thought to
originate from tubal epithelium via serous tubal intrae-
pithelial carcinoma (STICs) [24, 25, 33]. We noticed
that FOLR1 mRNA expression is significantly stronger
in both the tubal healthy epithelium and the type II
cancers than in normal ovarian epithelium together
with borderline tumours and type I cancers. These
observations suggest that mRNA expression of FOLR1
Fig. 2 Survival curves (entire follow-up period) according to FOLR1 mRNA expression in the whole ovarian cancer cohort and stratified per FIGO
stage. Kaplan-Mayer curves and log-rank test were applied. Cut off for FOLR1 expression: median values in the cancer cohort (9.14). Units: FOLR1
mRNA expression: arbitrary units normalized to TBP
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in cancers is maintained from the cells of origin and
is cancer type-specific.
Moreover, we are able to underscore the hypothesis
established by others [34, 35], namely that strong FOLR1
mRNA expression appears to be related to a more ag-
gressive cancer phenotype, as shown by the association
with higher-graded tumours, more residual disease after
primary debulking surgery, and the association with
advanced FIGO stages.
Accordingly, univariate survival analyses for the entire
cohort of patients revealed poor clinical outcome in
terms of PFS and OS when FOLR1 mRNA expression
was up-regulated, but this was not verified when type I
and type II cancers were assessed separately. Similarly,
RT-PCR based results reported by the by Siu et al. [35]
did not reveal prognostic relevance for FOLR1 expres-
sion. However, the study of Chen et al. [34] reported an
independent worse DFS and OS for high levels of
FOLR1 in serous ovarian cancers in a RT-PCR based
analysis.
Type I cancers are known for their poor constitutive
responsiveness to chemotherapy including platinum
agents and, as already mentioned, FOLR1 expression has
been found to be significantly weaker in type I and type
II cancers. Of special note, however is, that a subgroup
of type I cancers showing FOLR1 expression above
median value 9.14 exhibited a far stronger sensitivity to
platinum treatment than did the large majority of type I
tumours. Even if we used the classical arbitrary thresh-
old of the six-month platinum-free interval to assign
platinum sensitivity as defined by Markman et al. [26],
which may be less appropriate in type I cancers due to
their low constitutive proliferation, it appears that this
subgroup of relatively “strong” FOLR1 mRNA-expressing
type I cancers has a more aggressive phenotype that is
closer to that of type II cancers and may thus be
more susceptible to platinum agents. Nonetheless, we
were not able to show this relationship in type II
ovarian cancers, which show a priori stronger FOLR1
mRNA expression. Contrary to our findings, others
reported FOLR1 expression to be predictive for poor
platinum response in serous cancers [34], or were
unable to detect a relationship between FOLR1
expression and chemosensitivity [35].
Fig. 3 Survival curves limited to the first 12 months according to FOLR1 mRNA expression in type I and II cancers for FIGO stage III-IV. Kaplan-Mayer
curves and log-rank test were applied. Cut off for FOLR1 expression: median values in the cancer cohort (9.14). Units: FOLR1 mRNA expression: arbitrary
units normalized to TBP
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Table 3 One-year follow-up univariate and multivariate survival analysis in FIGO stage III-IV for FOLR1 mRNA expression
Univariatea Multivariateb
PFS OS PFS OS
Months
(median)
CI 95 % HR p value Months
(median)
CI 95 % HR p value HR CI 95 % p value HR CI 95 % p value
Type I FOLR1 mRNA
expressionc
Weak 8.56 7.06-10.06 0.246 [0.081-0.743] 0.006** 10.25 9.06-11.44 0.093 [0.012-0.717] 0.004** 0.38 0.16-0.87 0.023* 0.59 0.007-0.52 0.011*
Strong 11.25 10.08-12.41 11.64 10.95-12.33
Grading G1 VS G2-3 0.62 0.35-1.65 0.416 1.11 0.29-4.18 0.880
Age < o >
median
0.76 0.36-1.58 0.461 1.46 0.69-3.05 0.317
Residual disease 0 VS >0 2.04 0.71-5.83 0.183 1.33 0.37-4.29 0.661
histologyd 1.73 0.94-3.37 0.077 2.01 0.94-4.29 0.071
FIGO stage I-II VS III-IV 2.08 0.84-5.11 0.110 1.01 0.30-3.83 0.982
Type II FOLR1 mRNA
expressionc
Weak 9.17 7.94-10.40 0.904 [0.577-1.414] 0.183 11.25 10.38-12.12 0.586 [0.170-2.023] 0.390
Strong 10.30 9.57-11.02 11.68 11.30-12.05
Cut off for FOLR1 mRNA expression =median value in the cancer cohort (9.14) *Significant at the 0.05 level, **Significant at the 0.01 level alog rank test, bCOX-regression analysis;












Although, FOLR1 appeared to be related to the aggres-
siveness of the disease, a peculiar transitory inverted
effect in the one-year survival analysis was detected. In
FIGO stage III and IV type I cancers showed independ-
ent better PFS and OS for high levels of FOLR1 mRNA
expression. This small and transitory PFS and OS effects
might be consistent with the association of FOLR1
expression with platinum sensitivity in type I cancers.
Even though Immunohistochemistry evaluation is not
directly comparable with results obtained with RT-PCR,
a similar transient inverted time limited effect was
already described by Köbel et al. [36]. These authors
found, for high values of FOLR1 mRNA expression, a
better independent OS for serous cancers in the first
two years follow-up.
A further important aspect of the determination of
FOLR1 expression is that FOLR1 may potentially repre-
sent a molecule of major interest as a target for folate-
conjugates using highly efficient drugs and the principal
efficacy of this treatment option has already been evalu-
ated together with a highly predictive companion diag-
nostic in clinical trials [37]. Probably those patients with
type I cancers and high expression of FOLR1 may bene-
fit from these treatments.
Another goal of our work was to investigate whether
FOLR1 expression is associated with the degree of global
DNA hypomethylation, which is considered to be a sign
of unfavourable prognosis in ovarian cancer [38]. It has
been shown that folate depletion, which potentially
causes upregulation in FOLR1 expression [22, 23], in-
duces global DNA hypomethylation [39]. In fact, our re-
sults for the first time provide evidence that FOLR1
expression could be crucially involved in the modulation
of global DNA methylation especially in type II ovarian
cancer and possibly also in other malignancies.
LINE1 DNA was used as a direct marker for global
DNA hypomethylation. Our cohort of type I ovarian
cancers showed an independent worse PFS and OS for
high degree of LINE1 hypomethylation. This was in
agreement with our previous study [29] where poor PFS
and OS were found in mucinous ovarian cancers. How-
ever, in the present study we demonstrate a prognostic
value of LINE1 DNA hypomethylation not only in a spe-
cific histotype but also in a well genetically and clinically
characterized group of ovarian cancers, mainly the type I
cancers. Certainly, in depth investigations are requested
to confirm These Data to elucidate the underlined mo-
lecular mechanism connecting FOLR1 expression to the
global methylation status of ovarian cancers.
Conclusion
We conclude that according to FOLR1 expression our
data evidenced a completely different behaviour between
type I and type II ovarian cancers in terms of clinical
Fig. 4 Kaplan Maier curves for LINE1 hypomethylation in type I and type II cancers. Kaplan-Mayer curves and log-rank test were applied. Cut off
for LINE1 hypomethylation: median value in cancer cohort. Units: LINE1 hypomethylation: PUMR values, percent of unmethylated reference
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Table 4 Univariateb and multivariate survivala analysis in type I and type II cancers for LINE1 DNA hypomethylation
Univariate Multivariate
PFS OS PFS OS
Months CI 95 % p value Months CI 9 5% p value HR CI 95 % p value HR CI 95 % p value
Type I LINE1 DNA hypomethylationc Low 208.9 154.8-262.8 0.011* 197.62 148.2-247.1 0.006** 6.13 1.24-30.22 0.026* 6.82 1.53-30.39 0.012*
High 48.1 18.7-77.5 67.9 24.5-111.3
Grading G1 VS G2-3 2.87 0.65-12.65 0.164 1.64 0.43-6.18 0.467
FIGO stage I-II VS III-IV 1.98 0.21-18.69 0.549 1.09 0.07-16.16 0.949
Age < o >median 0.61 0.11-3.27 0.566 3.84 1.09-13.52 0.036*
Residual disease 0 VS >0 5.16 2.76-9.64 <0.0001** 21.6 1.23-377.66 0.035*
Type II LINE1 DNA hypomethylationc low 51.4 15.0-87.8 0.791 86.10 38.7-133.5 0,878
high 42.7 15.7-69.8 68.97 38.9-98.9












outcome and platinum sensitivity. Thus, our findings on
FOLR1 add further considerable hints to the notion that
both types of ovarian cancer should be considered as
completely different clusters of tumors. Our results
prompt us to speculate that in type I cancers, which are
generally regarded to be chemoresistant, the subset of
strong FOLR1-expressing tumours are those, which may
benefit from platinum-based chemotherapy and may
furthermore have a special advantage from treatment
with folate-conjugates using platinum or other cytotoxic
agents.
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